What is the recommended treatment regimen for chronic cystitis, including acute therapy and prophylaxis?

Treatment of Chronic Cystitis

For chronic/recurrent cystitis, use nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days as first-line acute therapy, and when non-antimicrobial prophylaxis fails, implement continuous antimicrobial prophylaxis with nitrofurantoin, trimethoprim-sulfamethoxazole, or patient-initiated self-start therapy.

Critical Clarification: Chronic vs. Recurrent Cystitis

The term "chronic cystitis" requires immediate clarification, as the available high-quality guidelines address recurrent uncomplicated cystitis (≥3 UTIs/year or ≥2 UTIs in 6 months), not truly chronic inflammation 1, 2, 3. The IDSA/ESCMID guidelines explicitly state that "management of recurrent cystitis...is not addressed in this guideline" 1, though they provide the foundation for acute episode treatment. The most recent EAU 2024 guidelines 2 and AUA/CUA/SUFU 2019 guidelines 3 fill this gap with specific recurrent UTI management strategies.

Acute Episode Treatment

First-Line Agents (in order of preference):

1. Nitrofurantoin monohydrate/macrocrystals: 100 mg twice daily for 5 days 1, 2, 3

• Clinical cure rate: 93% (84-95%)
• Microbiological cure: 88% (86-92%)
• Minimal resistance and collateral damage
• This is the optimal choice balancing efficacy and antimicrobial stewardship

2. Trimethoprim-sulfamethoxazole: 160/800 mg (1 DS tablet) twice daily for 3 days 1, 2

• Only use if local resistance rates <20% 1
• Clinical cure: 93% (90-100%)
• If resistance exceeds 20%, this agent should NOT be used empirically

3. Fosfomycin trometamol: 3 g single dose 1, 2

• Convenient single-dose therapy
• Clinical cure: 91%
• Caveat: Inferior microbiological efficacy (80%) compared to other first-line agents 1

Alternative Agents (when first-line cannot be used):

• Pivmecillinam: 400 mg three times daily for 3-5 days (Europe only) 1, 2
• β-lactams (amoxicillin-clavulanate, cefdinir, cefaclor, cefpodoxime): 3-7 days 1
  • Use with caution: inferior efficacy and more adverse effects
  • Generally inferior to first-line agents

Agents to AVOID:

• Fluoroquinolones should be RESERVED for complicated infections, NOT routine cystitis 1, 2
  • High collateral damage despite excellent efficacy
  • Reserve for pyelonephritis or resistant organisms
• Amoxicillin/ampicillin: DO NOT USE empirically due to high resistance rates 1

Management Algorithm for Recurrent Episodes

Step 1: Confirm Diagnosis

• Obtain urine culture and sensitivity BEFORE each treatment 3
• Document positive cultures to establish true recurrence pattern
• Rule out alternative diagnoses if symptoms don't correlate with cultures

Step 2: Treat Acute Episodes

• Use shortest effective duration (generally ≤7 days) 3
• Select agent based on culture sensitivities and local resistance patterns
• Patient-initiated self-start therapy is appropriate for select patients while awaiting cultures 3

Step 3: Implement Prophylaxis Strategy

Non-Antimicrobial Interventions (try FIRST): 2

1. Vaginal estrogen (postmenopausal women): STRONG recommendation 2

   • Most effective non-antimicrobial intervention

2. Immunoactive prophylaxis: STRONG recommendation 2

   • Reduces recurrence across all age groups

3. Methenamine hippurate: STRONG recommendation 2

   • Effective in women without urinary tract abnormalities

4. Increase fluid intake (premenopausal women) 2

5. Consider (weaker evidence):

   • Probiotics with proven vaginal flora strains 2
   • Cranberry products (contradictory evidence) 2
   • D-mannose (weak evidence) 2
   • Intravesical hyaluronic acid ± chondroitin sulfate (when other approaches fail) 2

Antimicrobial Prophylaxis (when non-antimicrobial measures fail): 2, 3, 4

• Continuous prophylaxis: Low-dose nitrofurantoin, trimethoprim-sulfamethoxazole, or fluoroquinolone
• Postcoital prophylaxis: Same agents, single dose after intercourse
• Patient-administered intermittent therapy: Self-start at symptom onset 3, 4
  • Effective alternative to continuous prophylaxis
  • Requires reliable patient compliance

Critical Pitfalls to Avoid

1. Do NOT treat asymptomatic bacteriuria 3

   • No surveillance urine cultures in asymptomatic patients
   • Treatment provides no benefit and promotes resistance

2. Do NOT perform routine imaging or cystoscopy in women <40 years without risk factors 2

   • Extensive workup not indicated for uncomplicated recurrent cystitis

3. Do NOT use fluoroquinolones as first-line therapy 1

   • Reserve for complicated infections or resistant organisms
   • Significant collateral damage to gut/vaginal flora

4. Do NOT exceed 7 days of treatment for acute episodes 3

   • Longer courses increase resistance without improving outcomes

5. Verify local resistance patterns before empiric trimethoprim-sulfamethoxazole use 1

   • If >20% resistance, choose alternative agent

Duration and Monitoring

• Acute episodes: 3-7 days maximum 1, 3
• Prophylaxis duration: Continue as long as benefit persists; can be used for years 4
• Follow-up cultures: Only if symptoms persist or recur within 2 weeks 2
• No routine post-treatment cultures in asymptomatic patients 2

Special Considerations

Men with recurrent cystitis: 2

• Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 7 days
• Fluoroquinolones acceptable based on susceptibility testing
• Longer treatment duration than women due to prostatic involvement

Resistance-driven therapy:

• If oral antibiotics ineffective, use culture-directed parenteral antibiotics for ≤7 days 3

This algorithmic approach prioritizes antimicrobial stewardship while maintaining clinical efficacy, with clear escalation pathways when initial strategies fail.